$IMA News

Wedbush Reiterates Underperform on ImageneBio, Maintains $2 Price Target

ImageneBio Q1 EPS $(0.95) Misses $(0.70) Estimate

ImageneBio $30 Million Private Placement Ignites Stock

ImageneBio shares are trading higher after the company announced it entered into a $30 million definitive securities purchase agreement with certain institutional investors in a private placement.

ImageneBio shares are trading higher after the company announced it entered into a $30 million definitive securities purchase agreement with certain institutional investors in a private placement.

ImageneBio Raises $30M Via Private Institutional Placement To Fund Hair Loss And Skin Disease Treatments

ImageneBio Q4 EPS $(6.73) Misses $(1.44) Estimate

Wedbush Assumes ImageneBio at Underperform, Announces Price Target of $2

ImageneBio Announces It Intends To Submit Protocol Amendment For Phase 2b ADAPTIVE Study To Expand Number, Exposure Range Of Dosing Regiments, Optimize Feasibility Of Study

ImageneBio Q3 EPS $(2.91) Misses $(1.28) Estimate

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

ImageneBio On Oct 23, Elects Not To Renew Agreement With Miragene; Extends Term For Miragene Services By Six Months; Total Fees For Miragene Extension Services Are $200K

This Albemarle Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Leerink Partners Initiates Coverage On ImageneBio with Outperform Rating, Announces Price Target of $30

ImageneBio CFO Jotin Marango Resigns Effective October 20, 2025

Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals